Genmab — Juli 2024
-
JKY, ang royalty satser, kommer Hexcd38 nok aldrig op på samme top revenues som DARA, men grundet 20% for longer/more kunne Hexabody godt bliver endnu mere værd for Gmab. Epco og Gen1046 er 50/50 og har for Gmab begge potentiale til at bliver større revenuemæssigt end DARA, men driver jo også omkostninger som DARA ikke gør, så man kan ikke sammenligne Epco/Gen1046 revenues med dara revenues 1:1.
-
Er der nogen der ved om Genmab evt kan forny deres CD38 patent https://patents.google.com/patent/JP2024075737A/en
-
Godmorgen
-
Ben Derman
@bdermanmd
Let’s talk about freedom…from spending as much time in clinic!We piloted discontinuation of premeds for daratumumab starting cycle 2 (we kept dex) and had no adverse events! https://x.com/bdermanmd/status/1808701446549807569
-
-
The New England Journal of Medicine - Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2313811
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind